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A Randomized, Controlled Trial of Catheter-Related Infectious Event 
Rates Using Antibiotic-Impregnated Catheters Versus Conventional 
Catheters in Pediatric Cardiovascular Surgery Patients 
 
Elaine G. Cox, Chad A. Knoderer, Aimee Jennings, John W. Brown, Mark D. Rodefeld, Scott G. Walker, and Mark 
W. Turrentine 
 
We conducted a randomized, controlled clinical trial to determine whether a difference in catheterassociated 
blood stream infection (CABSI) incidence existed between children who underwent cardiac 
surgery and had a central venous catheter impregnated with minocycline and rifampin versus those 
who had a conventional, nonimpregnated catheter after cardiac surgery. Due to a lower number of 
infections than expected, the study was terminated early. Among 288 evaluable patients, the rates of 
CABSI and line-related complications were similar between the 2 groups. 
 
BACKGROUND 
 
Central venous catheter (CVC) use is associated with high risk of catheter-associated blood 
stream infection (CABSI), increases in morbidity and mortality, and is a significant cost driver. 
These issues tend to be more complicated in children in whom dependence on central catheters 
has increased because of limitations on access options. With technical issues compounding 
placement in ill children, rate of catheter colonization is high and approximately 8% result in 
infection [1]. Pediatric cardiac intensive care unit (PICU) patients are at higher risk for CABSI 
because of the presence of multiple catheters, long hospitalization, increased transfusions, and 
prolonged high levels of support, including extracorporeal membrane oxygenation (ECMO) [2]. 
 
Efforts to decrease hospital-associated infections intensified after CABSI was declared a “never 
event” by the Centers for Medicare and Medicaid, and the effectiveness of antibiotic-
impregnated catheters in further reducing infections has gained much interest [3]. Because of the 
paucity of controlled trials of antibiotic-impregnated catheters in children, efficacy and safety 
questions remain. Our objective was to determine whether a difference in CABSI incidence 
existed between CVCs impregnated with minocycline and rifampin (M/R) versus conventional, 
nonimpregnated (C/S) catheters used in children after cardiac surgery. 
 
METHODS 
 
Patients were eligible for the study if they were <18 years of age, underwent cardiovascular 
surgery from October 2006 to March 2010 at Riley Hospital for Children, and had a case 
complexity that warranted a CVC placement for longer than 3 days. Exclusion criteria were as 
follows: (1) drug allergy to minocycline, other tetracyclines, or rifampin; (2) ventricular assist 
device therapy; (3) ECMO therapy; (4) cardiac transplant; (5) active infection; and (6) delayed 
closure of sternum. The study was approved by the Institutional Review Board at Indiana 
University. 
 
The study was a prospective, randomized controlled trial. Patients undergoing cardiac surgery 
who required placement of a double lumen central venous catheters (4 Fr, 8 cm, 5 Fr, 8 cm or 12 
cm long: Cook Critical Care, Bloomington, IN) were randomized with 1:1 allocation to receive 
either the M/R or the C/S catheter. Study catheters were assigned a random identification number 
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(by Cook Critical Care) and packed in identical catheter trays. The randomization scheme 
consisted of blocks of six identical catheter trays stocked with the above catheters in a 
randomized sequence. Although the color of the SPECTRUM catheter was unique and visible to 
the inserting physician at the time of implantation, it was not documented and was not visible 
after it placement. Thus, the clinical and infection control teams were in effect blinded to study 
arm into which each patient had been assigned. Catheters were inserted into the subclavian, 
femoral, or jugular vein under full sterile conditions in 1 of 2 designated operating rooms by 
cardiovascular surgeons and anesthesiologists only. Skin preparation was in compliance with 
guidelines with betadine for those patients younger than 2 months of age, and ChloraPrep was 
used for older patients. Full patient draping was used on every case. Surgery-related data 
included placement location, inserting physician, cardiac defect, cardiac repair, cardiopulmonary 
bypass time, ischemic time, cut time, and intraoperative antibiotic administration. Cefuroxime 
was the standard postoperative antibiotic, which is routinely given at our hospital for 
cardiovascular surgery prophylaxis and administered for 24 hours. Patients with an allergy 
received either vancomycin or clindamycin prophylaxis. Postoperative care was done in the 
PICU and the Heart Center step down unit managed by the pediatric cardiovascular team. 
 
The standard of care for incisions included a semipermeable membrane dressing that was 
changed every 96 hours. When present, gauze dressings were changed every 48 hours. Catheter 
site assessment was made with each dressing change, and the surrounding area was disinfected 
with a chlorhexidine solution. Administration sets and all add-on devices were changed routinely 
every 96 hours and every 24 hours when blood or lipids were infused, per hospital policy. 
 
The primary outcome measure was incidence of CABSI per 1000 catheter days per standard 
terminology. All CABSIs were determined by hospital infection control specialists according to 
accepted National Healthcare Safety Network criteria at the time of study. Quantitative cultures 
and differential time to positivity were not available at the microbiology laboratory of the study 
institution. A secondary outcome measure was episodes of clinical sepsis and/or infection with 
identified source other than the CVC. 
 
Daily evaluation through hospital discharge included fever, blood pressure, white blood cell 
count, platelet count, glucose, arrhythmia, urine output, or additional antibiotic administration. 
Any catheter related complication, including pneumothorax, thrombosis, occlusion, 
displacement, leakage, fracture, or fragmentation, was recorded. 
 
Categorical measures were tabulated, and treatment differences were assessed with a χ2 or 
Fisher’s exact test. Continuous measures were summarized using means and standard deviations. 
Analysis was performed on an intention-to-treat basis. According to protocol, a blinded interim 
analysis was performed by an independent data safety monitoring board upon 50% (290 patients) 
of study enrollment. 
 
RESULTS 
 
The total number of enrolled patients was 326 with 288 deemed evaluable. Reasons for exclusion 
included: open chest (10), ECMO (5), inability to place catheter (16), catheter inadvertently 
inserted in wrong vessel (3), preexisting infection (1), no assent obtained (1), biopatch instead of 
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standard dressing (1), and study catheter placed and removed in the operating room (1). Groups 
were evenly split between the 2 catheters (M/R = 146, C/S = 142). Demographics, RACHS-1 
scores, and procedural information did not vary significantly between groups (Table 1). The 
number of catheter days were similar (M/R = 866 and C/S = 828). 
 
The number of infections was exactly the same with 3 in each group. Rates of CABSI in both 
groups were quite small (M/R = 3.46/1000 catheter days and C/S = 3.62/1000 catheter days), and 
there was no statistically significant difference between the 2 groups (95% confidence interval, –
3.4%–3.2%; P > .99). All 6 CABSIs were noted to occur in children <2 years of age. Three 
infections occurred in the internal jugular location (M/R = 2 and C/S = 1), 2 in the femoral 
location (C/S = 2), and 1 in the subclavian vein (M/R = 1). Organism and line day of infection 
also were not significantly different between groups with Escherichia coli and Streptococcus 
mitis in the M/R group on days 3 to 17; and coagulase-negative staphylococcus, methicillin-
susceptible Staphylococcus aureus, and Candida albicans being recovered on days 5–11 in the 
C/S catheters. 
There were no statistically significant differences in catheter complications between groups as 
shown in Table 1, and, overall, complications were rare in either group in every category. 
Noncatheter-related infections did not differ between groups. There were 8 of 146 (rate = 9.24) 
in the M/R group and 4 of 141 (rate = 8.48) in the C/S group (P = .38). 
 
Results of the interim analysis demonstrated that the expected infection rate was substantially 
less than postulated and resulted in no overall statistical difference with regard to infectious 
outcomes between catheters. It was expected that the study would be highly unlikely to show a 
statistical difference, even with the substantial additional enrollment, and was therefore stopped. 
 
 
 M/R(n= 146) C/S (n= 142) P Value 
Demographics     
Age (month)a  12 (6.6–29.3)  12.9 (5.9–42.3)  .88  
Weight (kg)a  8.8 (6.5–13)  8.9 (5.8–13.7)  .68  
Gender (male) Cardiopulmonary bypass time (minutes)b Anesthesia 
time (minutes)b Ischemic time (minutes)b Surgery duration 
(minutes)b OR time (minutes)b  
51.4% 97.6 ± 48.9 371.1 ± 
73 43.3 ± 31.8 212.5 ± 77.2 
371.8 ± 72.4  
53.5% 103.9 ± 55.7 375.4 ± 
87.0 43.9 ± 30.6 214.5 ± 82.8 
376.3 ± 87.5  
.72 .31 .64 
.88 .84 .63  
Outcomes     
ICU daysa  3(2–4)  2 (1–4)  .71  
Total hospital duration (days)a  6(5–10)  6 (4–9)  .74  
Antibiotic daysa  6(3–11.5)  3.5 (2–7)  .19  
All complications  10.3%  12%  .7  
Hemothorax  0.7%  0%  >.99  
Bleeding at catheter insertion site  1.4%  0%  .49  
Venous thrombosis (in cannulated blood vessel)  0%  0.7%  .49  
Catheter leak (requiring repair or removal)  2.1%  2.1%  >.99  
Catheter displacement (requiring replacement)  0%  0.7%  .49  
Catheter occlusion (requiring removal or thrombectomy)  2.7%  3.5%  .74  
Other catheter-related complications  4.8%  7%  .46  
 
Table 1 Primary Results 
Abbreviations: C/S, nonimpregnated catheters; ICU, intensive care unit; OR, operating room; M/R, minocycline and rifampin-coated catheters. 
aData reported as median (interquartile range). 
bData reported as mean (+/– standard deviation). 
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DISCUSSION 
 
With an increasing focus on infection risk, central catheter bundles have been used in efforts to 
prevent CABSI. Implementation has been effective in adults but there is limited evidence in 
children. Berneholtz et al [4] demonstrated a reduction in CABSI rate from 7.7 to 1.4 after 
implementation of such techniques, and others have shown benefits as well [5].  
 
Utilization of chlrohexidine-silver-coated catheters led to a minimal decrease in CABSI that is 
beyond that seen based on education alone [6]. Early studies demonstrated decreased catheter 
colonization and were suggestive of decreased infection with a possible associated cost savings, 
although [7, 8] the decreased microbe colonization could not be directly translated to decreased 
infection [9, 10]. One observational trial in critically ill children demonstrated longer onset to 
infection compared with conventional catheters [11]. 
 
Our study demonstrates no statistical differences in CABSI in children after cardiac surgery in 
M/R compared with C/S catheters. CABSI secondary to a staphylococcal organism was not 
observed in the M/R catheters. No infections occurred in patients older than 2 years of age and 
none in the M/R catheters placed in the femoral location, often the easiest access in small 
children. Further studies may be warranted to assess the impact that M/R catheters may have in 
these populations. Our study raises the question that perhaps antibiotic-impregnated catheters 
cannot lower CABSI rates further when they are already extremely low; however, in areas that 
have applied measures without reaching the desired goals, there could be some benefit in adding 
these catheters. 
 
Anecdotally, practitioners have commented that the antibiotic-impregnated catheters are more 
difficult to insert and have increased complications. Our data dispute this assertion because there 
were no statistically significant differences in any of the complications when comparing M/R 
versus C/S catheters. However, the study lacked sufficient power to make definitive statements 
regarding complications. 
 
During study enrollment, infection control led efforts to reduce the PICU CABSI rate and 
resulted in a decrease in overall line infection rate from a monthly peak of 14.5 to a low of 0.0 
and an average of less than 4 per 1000 catheter days during our study period. This reduction in 
baseline CABSI resulted in the study being underpowered to detect a significant difference 
between catheters and is a significant limitation, making it difficult to pinpoint the independent 
impact of the catheters. Because of low rates of infection, only a large multicenter study is likely 
to generate the numbers required for statistical power. 
 
CONCLUSIONS 
 
Our results indicate that the M/R catheter can be safely used in children, including those who 
weigh less than 10 kg, despite no current US Food and Drug Administration guidelines for that 
age group. No difference was observed in infectious outcomes between M/R and C/S central 
venous line catheters, possibly due to the extremely low baseline infection rate. There is no 
evidence that complications are increased with their use. Further studies with larger subject 
enrollment may be necessary to definitively answer such questions. 
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